Abstract. GOLPH3 was originally identified by proteomic analyses of Golgi proteins localized in the trans-Golgi network. Recently, it was reported that GOLPH3 is up-regulated in various types of malignancies, including melanoma, colon cancer and lung cancer. However, the mechanism through which GOLPH3 is involved in the pathogenesis of rhabdomyosarcoma remains unidentified. In order to explore the function of GOLPH3 and its isoform, GOLPH3L, in the pathogenesis of rhabdomyosarcoma, we investigated the expression and knockdown effects of GOLPH3 and GOLPH3L in human rhabdomyosarcoma. Western blot analysis and real-time PCR revealed that human rhabdomyosarcoma cell lines and biopsy specimens exhibited an increased expression of GOLPH3 and GOLPH3L. GOLPH3 and GOLPH3L knockdown by siRNA prevented the proliferation of human rhabdomyosarcoma cell lines. In addition, double-knockdown of GOLPH3 and GOLPH3L also prevented the proliferation of rhabdomyosarcoma cell lines. Our findings improve the understanding of rhabdomyosarcoma pathogenesis and suggest that the knockdown of GOLPH3 or GOLPH3L may be an effective treatment for rhabdomyosarcoma.

Introduction

Rhabdomyosarcoma, which is the most common soft-tissue sarcoma in children, includes two major subtypes, alveolar rhabdomyosarcoma and embryonal rhabdomyosarcoma. Approximately 70% of rhabdomyosarcoma patients without metastatic tumors are cured, but the prognosis of patients with metastasis or relapse remains dismal. Although numerous clinical trials have been performed, little improvement has been made for high-risk rhabdomyosarcoma patients, who have a 3-year overall survival of approximately 30% (1,2). Thus, improvements in outcome and in the understanding of the molecular pathways of rhabdomyosarcoma pathogenesis are a priority.

GOLPH3L (also known as GPP34R, GMx33β or FLJ10687) is an isoform of GOLPH3; these proteins are very homologous to each other and are similarly localized (4). Although the two isoforms are highly homologous in their amino acid sequences, the function of GOLPH3L has not yet been examined.

In the present study, we investigated the involvement of GOLPH3 and GOLPH3L in the pathogenesis of human rhabdomyosarcoma. We assessed the expression of GOLPH3 and GOLPH3L in rhabdomyosarcoma and the effect of GOLPH3 or GOLPH3L inhibition on the growth of rhabdomyosarcoma cells. We found that the knockdown of GOLPH3 or GOLPH3L may be an effective treatment for rhabdomyosarcoma.
examination revealed that patient 1 had embryonal rhabdomyosarcoma and patient 2 had alveolar rhabdomyosarcoma. Biopsy was performed before chemotherapy or radiotherapy for diagnosis. Control muscle was obtained from surgery for scoliosis. The study protocol was approved by the Institutional Review Board of Kagoshima University. All patients and controls provided written informed consent.

Real-time PCR. Real-time PCR was performed as previously reported (7). Briefly, each primer set used amplified a 160 to 200 bp amplicon. Reactions were run using SYBR Green (Bio-Rad, Hercules, CA, USA) on a MiniOpticon™ machine (Bio-Rad). The comparative C(t) (ΔΔCt) method was used to evaluate the fold change of mRNA expression. All PCR reactions were performed in triplicate, with 3 different concentrations of cDNA. All primers were designed using Primer3 software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3.cgi). The comparative C(t) (ΔΔCt) analysis method was used to evaluate the fold change of mRNA expression, using expression of GAPDH as a reference. The following primers were used: GOLPH3, 5'-AAGCCGTTCTTGACAAATGG-3' and 5'-GGTGTTGGCCTTCAAGATCCG-3'; GOLPH3L, 5'-ATGCCATCCAGAC-3' and 5'-TTTGGTCCCCTTCCACTTCAG-3'; GAPDH, 5'-GAAGGTGAAGGTCGGAGTC-3' and 5'-GAAGATGGTGATGGAGATTC-3'.

Western blot analysis. Western blotting was performed as previously reported (8). Approximately 20 µg of protein was loaded onto 4-12% NuPAGE precast gels (Invitrogen Corp., Carlsbad, CA, USA) and transferred to nitrocellulose membranes. The membranes were blocked in TBST buffer containing 10% milk for 1 h and then incubated with antibodies diluted in TBST. The following antibodies were used: anti-GOLPH3, anti-GOLPH3L (Sigma-Aldrich Co., St. Louis, MO, USA) and anti-tubulin (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Detection was performed using the ECL detection system (GE Healthcare Life Sciences, Giles, UK). Protein bands were visualized by LAS-4000mini (GE Healthcare Life Sciences, Tokyo, Japan).

MTT assay. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to evaluate cell proliferation, as previously described (9). Briefly, cells cultured on microplates were incubated with the MTT substrate for 4 h, rinsed with PBS, and subsequently lysed. The developed optical density was analyzed with a microplate reader (Bio-Rad Laboratories). GOLPH3 siRNA and GOLPH3L siRNA were purchased from Santa Cruz Biotechnology. Transfection of the siRNAs was performed according to the supplier's recommendations using Lipofectamine RNAiMax (Invitrogen).
Statistical analysis. All experiments were performed 3 times, except where otherwise stated, and samples were analyzed in triplicate. For real-time PCR experiments, each sample was tested using 3 different cDNA concentrations. Results are presented as mean (SD). The statistical differences between groups were assessed by applying a Student’s t-test for unpaired data, using Microsoft Office Excel (Microsoft Corp., Redmond, WA, USA) and Statistica (StatSoft Inc., Tulsa, OK, USA).

Results

Overexpression of GOLPH3 and GOLPH3L in human rhabdomyosarcoma cell lines. In order to assess the role of GOLPH3, we examined the expression of GOLPH3 in human rhabdomyosarcoma cell lines. Western blot analysis showed that the expression of GOLPH3 was up-regulated in human rhabdomyosarcoma cell lines. Western blot analysis showed that the expression of GOLPH3 was up-regulated in human rhabdomyosarcoma cell lines compared to mesenchymal stem cells. Furthermore, Western blot analysis showed that the expression of GOLPH3L, which is an isoform of GOLPH3, was also up-regulated in human rhabdomyosarcoma cell lines (Fig. 1A). It has been reported that GOLPH3L is expressed at levels of <2% in HeLa cells (10). Our Western blot results showed that both GOLPH3 and GOLPH3L resulted in intense bands. In order to compare the expression of GOLPH3 and GOLPH3L, we performed real-time PCR. Real-time PCR showed that the expression of GOLPH3L was 0.8- to 1.3-fold the expression of GOLPH3 (Fig. 1B).

Overexpression of GOLPH3 and GOLPH3L in human rhabdomyosarcoma biopsy specimens. We examined the expression of GOLPH3 and GOLPH3L with real-time PCR. Real-time PCR revealed that the expression of GOLPH3 and GOLPH3L was up-regulated between 4.6- and 33.8-fold and between 2.7- and 26.9-fold, respectively, in the 2 biopsy samples compared to normal skeletal muscle (Fig. 2A and B). Furthermore, real-time PCR revealed that the expression of GOLPH3L was 0.6- to 0.8-fold the expression of GOLPH3 (Fig. 2C). These findings suggest that the expression of GOLPH3 and GOLPH3L is up-regulated in human rhabdomyosarcoma.

Knockdown of GOLPH3 and GOLPH3L prevents human rhabdomyosarcoma cell proliferation. In order to examine the function of GOLPH3 in human rhabdomyosarcoma, the expression of GOLPH3 was knocked down with siRNA. Scrambled siRNA was used as a negative control. Western blot analysis showed that GOLPH3 siRNA decreased the expression of GOLPH3 in KYM-1, RD, and A204 human rhabdomyosarcoma cell lines (Fig. 3A). MTT assay showed that knockdown of GOLPH3 inhibited the proliferation of KYM-1, RD, and A204 cells (Fig. 3B-D). We next examined
the effects of GOLPH3L knockdown on rhabdomyosarcoma growth. Western blot analysis showed that GOLPH3L siRNA decreased the expression of GOLPH3L in the KYM-1, RD, and A204 cells (Fig. 4A). MTT assay showed that knockdown of GOLPH3L inhibited the proliferation of KYM-1, RD and A204 cells (Fig. 4B-D). Furthermore, we assessed the effect of knockdown of both GOLPH3 and GOLPH3L together. MTT assay showed that knockdown of GOLPH3 and GOLPH3L inhibited the proliferation of KYM-1, RD, and A204 cells (Fig. 5). These findings revealed that GOLPH3 and GOLPH3L knockdown inhibits human rhabdomyosarcoma growth.

Discussion

GMx33 is conserved from yeast to mammals, in which two very homologous forms, α and β have been noted (4). The human orthologs of GMx33α and β (GOLPH3 and GOLPH3L, respectively) were simultaneously identified through a separate proteomic analysis and described as Golgi-localized proteins (3,4). In addition, GOLPH3 has a large cytoplasmic pool (3). Cell-based assays confirmed that GOLPH3 can exchange between cytosolic and Golgi-associated pools rapidly, and the protein was additionally found to be associated with tubules and vesicles leaving the Golgi apparatus (5). In addition, GOLPH3 is localized to mitochondria (10). GOLPH3 is up-regulated in response to mitochondrial dysfunction in the muscle of mitochondrial disease (10). These findings suggest that GOLPH3 has various cytochemical functions other than the functions associated with being a Golgi-related protein.

We showed that the knockdown of GOLPH3 prevents the proliferation of human rhabdomyosarcoma. Although the precise function of GOLPH3 as an oncogene has not been elucidated, GOLPH3 has been implicated in protein trafficking, receptor recycling, and glycosylation, which are all processes involved in tumorigenesis (6,11). In addition, GOLPH3 interacts with a retromer complex, which is responsible for protein trafficking between endosomes and the trans-Golgi network (6,12). A role of the Golgi network in cancer pathogenesis has been reported, in that some oncoproteins, including RAS, are functionally active when localized in the Golgi network (13,14). GOLPH3 interacts with the VPS35 subunit of the retromer protein-recycling complex and enhances signaling through the mammalian target of rapamycin, which integrates input from multiple signaling pathways to control cell growth, proliferation, and survival (15). In addition, GOLPH3 enhances downstream growth signaling in response to receptor tyrosine kinase activation (6). The function of these molecular pathways in rhabdomyosarcoma pathogenesis should be examined.

An analysis of copy number alterations identified frequent regional amplification at 5p13 in multiple tumor types, including breast, colorectal and lung cancer (6). They reported that 5p13 copy number status was significantly correlated with gene expression of GOLPH3 in human lung cancer specimens, and subsequent functional studies pointed to GOLPH3 as a target for activation in cancers with 5p gain (6,11). We
showed that the expression of GOLPH3 and GOLPH3L is up-regulated in human rhabdomyosarcoma cell lines and biopsy specimens. GOLPH3L is located at 1q21.3. It has been reported that 1q21 is amplified in several human malignancies, including rhabdomyosarcoma (16-24). An amplification of 5p13 has not yet been reported in rhabdomyosarcoma. Another mechanism including epigenetic modification may affect the up-regulation of GOLPH3 and GOLPH3L as the process of gene transcription is regulated through the orchestration of many transcription factors and epigenetic mechanisms (25,26).

It has been reported that GOLPH3 is ubiquitously expressed and is not cell-specific (3). These findings suggest that knockdown of GOLPH3 results in toxicity in normal GOLPH3-expressing cells. Scott et al reported that the knockdown of GOLPH3 in low GOLPH3-expressing cells showed a minimal effect on cell proliferation, indicating that acute GOLPH3 depletions are not generally toxic to all cells (6). These findings suggest that the inhibition of GOLPH3 is an effective treatment for malignant tumors with GOLPH3 up-regulation.

GOLPH3L was also identified as a Golgi-localized protein with a large cytosolic pool (3,4). GOLPH3L was found to be expressed at a very decreased level compared to GOLPH3 in HeLa and NRK cells (5,10). Our Western blot analysis showed that GOLPH3L was expressed in a significant amount in bone marrow mesenchymal stem cells and human rhabdomyosarcoma stem cells, and GOLPH3L-specific siRNA reduced that expression. In addition, real-time PCR showed that GOLPH3L expression was abundant compared to GOLPH3 in RD, KYM-1 and A204 cells. These findings suggest that both GOLPH3 and GOLPH3L are expressed in human rhabdomyosarcoma cells. Although GOLPH3 and GOLPH3L share significant homology, there are different regions that have different functions. To the best of our knowledge, the function of GOLPH3L has not yet been examined. We showed that the knockdown of GOLPH3L prevents the proliferation of human rhabdomyosarcoma cell lines. These findings revealed that not only GOLPH3, but also GOLPH3L, may have oncogenic functions and that inhibition of GOLPH3L may be an effective treatment for malignant tumors with GOLPH3L up-regulation.

We performed an MTT assay following the double-knockdown of GOLPH3 and GOLPH3L. Although the MTT assay showed that double-knockdown prevents rhabdomyosarcoma cell proliferation statistically, double-knockdown did not have a synergistic effect. Real-time PCR showed that the knockdown efficiency of GOLPH3 or GOLPH3L siRNA was between 61 and 84% (data not shown). These findings suggest that the low levels of expression of GOLPH3 or GOLPH3L following siRNA treatment are due to an effect of cell proliferation. In addition, it has been reported that the deletion of yeast GOLPH3 (VPS74) had no effect on viability and growth (27). These findings suggest that the knockdown of GOLPH3 and GOLPH3L treatment does not inhibit tumor cell proliferation completely. To examine the precise function of GOLPH3 and GOLPH3L, a deletion examination in mammalian cells is needed.
In conclusion, our findings demonstrated that the expression of GOLPH3 and GOLPH3L was up-regulated in human rhabdomyosarcoma. These findings improve our understanding of rhabdomyosarcoma pathogenesis and suggest that the knockdown of GOLPH3 or GOLPH3L is an effective treatment for rhabdomyosarcoma.

Acknowledgements

We are grateful to Hui Gao for the excellent technical assistance. This study was supported by Grants-in-Aid for Scientific Research (KAKENHI) (B) 18390419, (C) 19591725, (C) 20591786, (C) 21591919, (C) 21591920, and (C) 22591663, and a Grant-in-Aid from the Ministry of Health, Labour, and Welfare of Japan for the Third Term Comprehensive Control Research for Cancer.

References